PARKINSON’S DISEASE This page intentionally left blank PARKINSON’S DISEASE: MOLECULAR AND THERAPEUTIC INSIGHTS FROM MODEL SYSTEMS

s.Betarbet, R., Na, H. M., Taylor, G., Bryant, M., andGreenamyre, J. T. ( 2005). Rotenone-induced substan-tia nigra pathology in mice. Society for Neuroscience Abstracts.Betarbet , R., Canet-Aviles, R. M., Sherer, T. B.,Mastroberardino, P. G., McLendon, C., Kim, J. H.,Lund, S., Na, H. M., Taylor, G., Bence, N. F.,Kopito, R., Seo, B. B., Yagi, T., Yagi, A., Klinefelter, G.,Cookson, M. R., and Greenamyre, J. T. (2006).Intersecting pathways to neurodegeneration inParkinson’s disease: Effects of the pesticide rotenoneon DJ-1, alpha-synuclein, and the ubiquitin–protea-some system. Neurobiol Dis 22, 404–420 .Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O.,Breedveld, G. J., Krieger, E., Dekker, M. C., Squitieri, F.,Ibanez, P., Joosse, M., van Dongen, J. W., Vanacore, N.,van Swieten, J. C., Brice, A., Meco, G., van Duijn, C. M.,Oostra, B. A., and Heutink, P. (2003). Mutations ins.Betarbet , R., Canet-Aviles, R. M., Sherer, T. B.,Mastroberardino, P. G., McLendon, C., Kim, J. H.,Lund, S., Na, H. M., Taylor, G., Bence, N. F.,Kopito, R., Seo, B. B., Yagi, T., Yagi, A., Klinefelter, G.,Cookson, M. R., and Greenamyre, J. T. (2006).Intersecting pathways to neurodegeneration inParkinson’s disease: Effects of the pesticide rotenoneon DJ-1, alpha-synuclein, and the ubiquitin–protea-some system. Neurobiol Dis 22, 404–420 .Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O.,Breedveld, G. J., Krieger, E., Dekker, M. C., Squitieri, F.,Ibanez, P., Joosse, M., van Dongen, J. W., Vanacore, N.,van Swieten, J. C., Brice, A., Meco, G., van Duijn, C. M.,Oostra, B. A., and Heutink, P. (2003). Mutations in the DJ-1 gene associated with autosomal recessiveearly-onset parkinsonism. Science 299, 256–259.Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., andDel Tredici, K. ( 2004). Stages in the development ofParkinson’s disease-related pathology. Cell Tissue Res318, 121–134 .Braak, H., de Vos , R. A., Bohl, J., and Del Tredici , K.(2006). Gastric alpha-synuclein immunoreactive inclu-sions in Meissner’s and Auerbach’s plexuses in casesstaged for Parkinson’s disease-related brain pathology.Neurosci Lett 396, 67–72.Coulom, H., and Birman, S. (2004). Chronic exposureto rotenone models sporadic Parkinson’s disease in Drosophila melanogaster. J Neurosci 24, 10993–10998.Dawson, T. M., and Dawson, V. L. (2003). Molecularpathways of neurodegeneration in Parkinson’s disease .Science 302, 819–822. RODENT TOXIN MODELS204 Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F.,Agid, Y., Lees, A., Jenner, P., and Marsden, C. D.(1989). Basal lipid peroxidation in substantia nigrais increased in Parkinson’s disease. J Neurochem 52,381–389 .Duda , J. E., Giasson , B. I., Mabon, M. E., Lee, V. M., andTrojanowski, J. Q. (2002). Novel antibodies to synu-clein show abundant striatal pathology in Lewy bodydiseases. Ann Neurol 52 , 205–210.Dunnett, S. B., and Bjorklund, A. (1999). Prospects fornew restorative and neuroprotective treatments inParkinson’s disease. Nature 399, A32–aA39 .Ferrante , R. J., Schulz, J. B., Kowall , N. W., and Beal, M. F.(1997). Systemic administration of rotenone pro-duces selective damage in the striatum and globus pal-lidus, but not in the substantia nigra. Brain Res 753,157–162 .Gao, H. M., Jiang, J., Wilson, B., Zhang, W., Hong, J. S.,and Liu, B. (2002). Microglial activation-mediateddelayed and progressive degeneration of rat nigraldopaminergic neurons: Relevance to Parkinson’s dis-ease. J Neurochem 81, 1285–1297 .Gibb , W. R., and Lees, A. J. ( 1989). The significanceof the Lewy body in the diagnosis of idiopathicParkinson’s disease. Neuropathol Appl Neurobiol 15,27–44.Greenamyre, J. T., and Hastings, T. G. ( 2004).Biomedicine. Parkinson’s – divergent causes, conver-gent mechanisms. Science 304, 1120–1122 .Greenamyre, J. T., Sherer, T. B., Betarbet, R., and Panov, A. V.(2001). Complex I and Parkinson’s disease. IUBMBLife 52, 135–141.Greenamyre, J. T., Nichols , C. J., Na, H. M., Martin, B.,Postupna , N., Reinhardt, J., Anderson, M., andBetarbet, R. (2004). Rotenone-induced parkinso-nian pathology in non-human primates. Society for Neuroscience Abstracts.Greene , J. C., Whitworth, A. J., Kuo, I., Andrews, L. A.,Feany, M. B., and Pallanck, L. J. (2003).Mitochondrial pathology and apoptotic muscle degen-eration in Drosophila parkin mutants . Proc Natl AcadSci USA 100, 4078–4083 .Haas, R. H., Nasirian, F. , Nakano, K., Ward, D., Pay, M.,Hill , R., and Shults , C. W. (1995). Low platelet mito-chondrial complex I and complex II/III activity inearly untreated Parkinson’s disease. Ann Neurol 37,714–722 .Hague, S., Rogaeva, E., Hernandez, D., Gulick, C.,Singleton, A., Hanson , M., Johnson , J., Weiser, R.,Gallardo , M., Ravina, B., Gwinn-Hardy, K., Crawley, A.,St George-Hyslop , P. H., Lang, A. E., Heutink, P.,Bonifati, V., Hardy, J., and Singleton, A. (2003). Early-onset Parkinson’s disease caused by a compound het-erozygous DJ-1 mutation. Ann Neurol 54, 271–274 .Heikkila , R. E., Nicklas, W. J., and Duvoisin, R. C.(1985). Dopaminergic toxicity after the stereotaxicadministration of the 1-methyl-4-phenylpyridiniumion (MPP) to rats. Neurosci Lett 59, 135–140 .Hely, M. A., Morris, J. G., Reid, W. G., and Trafficante, R.(2005). Sydney Multicenter Study of Parkinson’s dis-ease: Non-l-dopa-responsive problems dominate at 15years. Mov Disord 20, 190–199 .Hisata, J. ( 2002). Lake and stream rehabilitation:Rotenone use and health risks. Final Supplement of the Environmental Impact Statement.Hoglinger, G. U., Carrard, G., Michel, P. P. , Medja, F.,Lombes, A., Ruberg, M., Friguet, B., and Hirsch, E. C.(2003a). Dysfunction of mitochondrial complex I andthe proteasome: interactions between two biochemi-cal deficits in a cellular model of Parkinson’s disease. JNeurochem 86, 1297–1307 .Hoglinger, G. U., Feger, J., Prigent, A., Michel, P. P. ,Parain, K., Champy, P. , Ruberg, M., Oertel, W. H. ,and Hirsch, E. C. ( 2003b). Chronic systemic complexI inhibition induces a hypokinetic multisystem degen-eration in rats. J Neurochem 84, 491–502 .Horgan, D. J., Ohno, H., and Singer, T. P. (1968). Studieson the respiratory chain-linked reduced nicotinamideadenine dinucleotide dehydrogenase. XV. Interactionsof piericidin with the mitochondrial respiratory chain.J Biol Chem 243, 5967–5976 .Hornykiewicz, O. ( 1966). Dopamine (3-hydroxytyramine)and brain function. Pharmacol Rev 18, 925–964 .Hunot, S., and Hirsch, E. C. (2003). Neuroinflammatoryprocesses in Parkinson’s disease. Ann Neurol 53(Suppl3), S49–sS58, discussion S58–S60.Inden, M., Kitamura, Y., Takeuchi, H., Yanagida, T.,Takata, K., Kobayashi, Y., Taniguchi, T., Yoshimoto , K.,Kaneko, M., Okuma, Y., Taira, T., Ariga, H., andShimohama, S. (2007). Neurodegeneration of mousenigrostriatal dopaminergic system induced by repeatedoral administration of rotenone is prevented by 4-phe-nylbutyrate, a chemical chaperone. J Neurochem 101,1491–1504.Javitch, J. A., and Snyder, S. H. ( 1984). Uptake ofMPP( ) by dopamine neurons explains selectivityof parkinsonism-inducing neurotoxin, MPTP. Eur JPharmacol 106, 455–456 .Javitch, J. A., D’Amato, R. J., Strittmatter, S. M., andSnyder, S. H. (1985). Parkinsonism-inducing neuro-toxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine:Uptake of the metabolite N-methyl-4-phenylpyridineby dopamine neurons explains selective toxicity. ProcNatl Acad Sci USA 82, 2173–2177 .Jenner, P. ( 1998). Oxidative mechanisms in nigral celldeath in Parkinson’s disease. Mov Disord 13, 24–34.Klockgether, T. (2004). Parkinson’s disease: Clinicalaspects. Cell Tissue Res 318, 115–120. COMPLEX I INHIBITION, ROTENONE AND PARKINSON’S DISEASE205 Klockgether, T., and Turski , L. (1989). Excitatory aminoacids and the basal ganglia: Implications for thetherapy of Parkinson’s disease. Trends Neurosci 12,285–286 .Krige, D. , Carroll, M. T., Cooper, J. M., Marsden , C. D.,and Schapira, A. H. ( 1992). Platelet mitochondrialfunction in Parkinson’s disease. The Royal Kingsand Queens Parkinson Disease Research Group . AnnNeurol 32, 782–788 .Langston , J. W. (1996). The etiology of Parkinson’s dis-ease with emphasis on the MPTP story. Neurology 47,S153–sS160 .Langston , J. W. , Ballard, P., Tetrud, J. W., and Irwin, I.(1983). Chronic Parkinsonism in humans due to aproduct of meperidine-analog synthesis. Science 219,979–980 .Lapointe , N., St-Hilaire, M., Martinoli, M. G., Blanchet, J.,Gould, P., Rouillard , C. , and Cicchetti, F. (2004).Rotenone induces non-specific central nervous systemand systemic toxicity. FASEB J 18, 717–719 .Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S.,Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L.,Dawson, T. M., and Przedborski, S. (1999). Induciblenitric oxide synthase stimulates dopaminergic neuro-degeneration in the MPTP model of Parkinson disease.Nat Med 5, 1403–1409.Lotharius, J., and Brundin , P. ( 2002). Pathogenesis ofParkinson’s disease: Dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3, 932–942.Maslin, P. (2001). Rotenone . Pesticide News 54, 20–21.McNaught, K. S., and Jenner, P. (2001). Proteasomalfunction is impaired in substantia nigra in Parkinson’sdisease. Neurosci Lett 297, 191–194 .Mitsumoto , A., and Nakagawa, Y. (2001). DJ-1 is anindicator for endogenous reactive oxygen species elic-ited by endotoxin . Free Radic Res 35, 885–893.Mitsumoto , A., Nakagawa, Y., Takeuchi, A., Okawa, K.,Iwamatsu, A., and Takanezawa, Y. ( 2001). Oxidized forms of peroxiredoxins and DJ-1 on two-dimen-sional gels increased in response to sublethal levels ofparaquat. Free Radic Res 35, 301–310 .Na , H. M., Betarbet, R., Kim, J. H., Sherer, T. B.,and Greenamyre , J. T. (2003). Rotenone modelsof Parkinson’s disease selectively destroys striataldopaminergic terminals and spares postsynaptic stri-atal neurons. Society for Neuroscience Abstracts.Nicklas, W. J., Vyas , I., and Heikkila, R. E. (1985).Inhibition of NADH-linked oxidation in brain mito-chondria by 1-methyl-4-phenyl-pyridine, a metaboliteof the neurotoxin, 1-methyl-4-phenyl1,2,5,6-tetrahy-dropyridine. Life Sci 36, 2503–2508 .Parker, W. D., Jr, Boyson , S. J., and Parks, J. K. (1989).Abnormalities of the electron transport chain in idi-opathic Parkinson’s disease. Ann Neurol 26, 719–723.Przedborski, S., Jackson-Lewis, V.,Naini, A.B., Jakowec, M.,Petzinger, G., Miller, R., and Akram, M. (2001).The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of itsutility and safety. J Neurochem 76, 1265–1274.Richter, F., Hamann, M., and Richter, A. (2007). Chronicrotenone treatment induces behavioral effects but nopathological signs of parkinsonism in mice. J NeurosciRes 85, 681–691 .Rojo, A. I., Cavada, C., de Sagarra, M. R., and Cuadrado, A.(2007). Chronic inhalation of rotenone or paraquatdoes not induce Parkinson’s disease symptoms in miceor rats. Exp Neurol 208, 120–126.Saravanan, K. S., Sindhu, K. M., and Mohanakumar, K. P.(2005). Acute intranigral infusion of rotenone in ratscauses progressive biochemical lesions in the stria-tum similar to Parkinson’s disease. Brain Res 1049,147–155.Schapira , A. H., Cooper, J. M., Dexter, D., Jenner, P. ,Clark, J. B., and Marsden, C. D. (1989).Mitochondrial complex I deficiency in Parkinson’s dis-ease [letter] [see comments]. Lancet 1, 1269.Schuler, F., and Casida, J. E. (2001). Functional couplingof PSST and ND1 subunits in NADH:ubiquinoneoxidoreductase established by photoaffi nity labeling.Biochim Biophys Acta 1506, 79–87.Shamoto-Nagai, M., Maruyama, W., Kato, Y., Isobe, K.,Tanaka, M., Naoi, M., and Osawa, T. ( 2003). Aninhibitor of mitochondrial complex I, rotenone, inac-tivates proteasome by oxidative modification andinduces aggregation of oxidized proteins in SH-SY5Ycells. J Neurosci Res 74, 589–597 .Sherer, T. B., Betarbet, R., and Greenamyre, J. T.(2001). Pesticides and Parkinson’s disease. ScientificWorldJournal 1, 207–208.Sherer, T. B., Betarbet, R., Stout, A. K., Lund, S., Baptista, M.,Panov, A. V., Cookson, M. R., and Greenamyre, J. T.(2002). An in vitro model of Parkinson’s disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci22, 7006–7015.Sherer, T. B., Betarbet, R., Kim, J. H., and Greenamyre, J. T.(2003a). Selective microglial activation in the ratrotenone model of Parkinson’s disease. Neurosci Lett341, 87–90.Sherer, T. B., Kim, J. H., Betarbet, R., and Greenamyre, J. T.(2003b). Subcutaneous rotenone exposure causeshighly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179, 9–16.Sherer, T. B., Betarbet, R., Testa, C. M., Seo, B. B.,Richardson, J. R., Kim, J. H., Miller, G. W., Yagi, T.,Matsuno-Yagi, A., and Greenamyre, J. T. ( 2003c).Mechanism of toxicity in rotenone models ofParkinson’s disease . J Neurosci 23, 10756–10764 . RODENT TOXIN MODELS206 Shults, C. W. (2006). Lewy bodies. Proc Natl Acad SciUSA 103, 1661–1668 .Storch , A., Ludolph , A. C., and Schwarz, J. (2004).Dopamine transporter: Involvement in selectivedopaminergic neurotoxicity and degeneration. JNeural Transm 111, 1267–1286 .Talpade , D. J., Greene , J. G., Higgins, D. S., Jr, andGreenamyre, J. T. (2000). In vivo labeling of mito-chondrial complex I (NADH:ubiquinone oxidore-ductase) in rat brain using [(3)H]dihydrorotenone. JNeurochem 75, 2611–2621 .Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J.,Chan , P., Mayeux, R., and Langston, J. W. (1999).Parkinson disease in twins: An etiologic study. JAMA281, 341–346 .Thiffault, C., Langston, J. W. , and Di Monte , D. A.(2000). Increased striatal dopamine turnover follow-ing acute administration of rotenone to mice. BrainRes 885, 283–288 .Tipton , K. F., and Singer, T. P. (1993). Advances in ourunderstanding of the mechanisms of the neurotoxicityof MPTP and related compounds. J Neurochem 61,1191–1206 .Uversky, V. N. (2004). Neurotoxicant-induced animalmodels of Parkinson’s disease: Understanding the roleof rotenone, maneb and paraquat in neurodegenera-tion. Cell Tissue Res 318 , 225–241.Valente , E. M., Abou-Sleiman, P. M., Caputo, V.,Muqit, M. M., Harvey, K., Gispert, S., Ali, Z.,Del Turco, D., Bentivoglio, A. R., Healy, D. G. ,Albanese, A., Nussbaum, R., Gonzalez-Maldonado, R.,Deller, T., Salvi, S., Cortelli, P. , Gilks, W. P.,Latchman, D. S., Harvey, R. J., Dallapiccola, B.,Auburger, G., and Wood, N. W. (2004). Hereditaryearly-onset Parkinson’s disease caused by mutations inPINK1. Science 304, 1158–1160 .Vehovszky, A., Szabo, H., Hiripi, L., Elliott, C. J., andHernadi, L. (2007). Behavioural and neural deficitsinduced by rotenone in the pond snail Lymnaea stag-nalis. A possible model for Parkinson’s disease in aninvertebrate. Eur J Neurosci 25, 2123–2130 .Yoritaka, A. , Hattori, N., Uchida, K., Tanaka, M.,Stadtman, E. R., and Mizuno, Y. (1996).Immunohistochemical detection of 4-hydroxynonenalprotein adducts in Parkinson disease. Proc Natl AcadSci USA 93, 2696–2701 .Yoshino, H., Nakagawa-Hattori, Y., Kondo, T., andMizuno, Y. (1992). Mitochondrial complex I and IIactivities of lymphocytes and platelets in Parkinson’sdisease. J Neural Transm Park Dis Dement Sect 4,27–34.Zhu, C., Vourc’h, P. , Fernagut, P. O., Fleming, S. M.,Lacan, S., Dicarlo, C. D., Seaman, R. L., andChesselet, M. F. (2004). Variable effects of chronicsubcutaneous administration of rotenone on striatalhistology. J Comp Neurol 478, 418–426 .